Clinical Trial Update: Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of gemcitabine, erlotinib, and sorafenib (GES) in metastatic pancreatic cancer has completed, with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Nexavar (Sorafenib)
• Tarceva (erlotinib)

Snippet

Sponsor: NYU Langone Health | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-12-21